Kymab Limited

Thomas Gallagher

Stephen D Gillies

Ian Kirby

Jamie Iain Campbell

Miha Kosmac

Volker Germaschewski

Cassandra Van Krinks

Nikole Sandy

Stephen John Arkinstall

Steve Arkinstall

Cecilia Deantonio

E-Chiang Lee

Matthew John McCourt

Richard Charles Alfred Sainson

Mohammed Hanif Ali

Joana De Abreu Carvalho

Rachael Jane Kimber

Nikole Sandy Nee Waddell

The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

Anti-PD-L1 antibodies

Anti-PD-L1 and IL-2 cytokines

The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo

Antibodies and immunocytokines

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.

Anti-ICOS antibodies

Growing community of inventors

Cambridge, United Kingdom

Thomas Gallagher